ArticleScience advances2020
Ultrasensitive and rapid quantification of rare tumorigenic stem cells in hPSC-derived cardiomyocyte populations.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Extracellular vesicles as bioactive nanotherapeutics: An emerging paradigm for regenerative medicine.Theranostics · 2022Pooled it
- Stem cell therapies for diabetes.Nature medicine · 2025Review
- A Capillary-Force-Driven, Single-Cell Transfer Method for Studying Rare Cells.Bioengineering (Basel, Switzerland) · 2024Article
- Phenotypic targeting using magnetic nanoparticles for rapid characterization of cellular proliferation regulators.Science advances · 2024Article
- A universal inverse design methodology for microfluidic mixers.Biomicrofluidics · 2024Article
- Seamless and non-destructive monitoring of extracellular microRNAs during cardiac differentiation from human pluripotent stem cells.Stem cell reports · 2023Article
- A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles.Nature communications · 2023Article
- A Micropillar Array Based Microfluidic Device for Rare Cell Detection and Single-Cell Proteomics.Methods and protocols · 2023Article
- Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting.Nature biomedical engineering · 2023Article
- Assessing Tumorigenicity in Stem Cell-Derived Therapeutic Products: A Critical Step in Safeguarding Regenerative Medicine.Bioengineering (Basel, Switzerland) · 2023Review
- A high-dimensional microfluidic approach for selection of aptamers with programmable binding affinities.Nature chemistry · 2023Article
- Characterization of human induced pluripotent stems cells: Current approaches, challenges, and future solutions.Biotechnology reports (Amsterdam, Netherlands) · 2023Review
- The functions and clinical application potential of exosomes derived from mesenchymal stem cells on wound repair: a review of recent research advances.Frontiers in immunology · 2023Review
- Review
- Genome-wide in vivo screen of circulating tumor cells identifiesScience advances · 2022Article
- Efficient recovery of potent tumour-infiltrating lymphocytes through quantitative immunomagnetic cell sorting.Nature biomedical engineering · 2022Article
- Article
- Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies.JCI insight · 2021Article
- Automated calibration of 3D-printed microfluidic devices based on computer vision.Biomicrofluidics · 2021Article
- A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.EBioMedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to detect rare human pluripotent stem cells (hPSCs) in differentiated populations is critical for safeguarding the clinical translation of cell therapy, as these undifferentiated cells have the capacity to form teratomas in vivo. The detection of hPSCs must be performed using an approach compatible with traceable manufacturing of therapeutic cell products. Here, we report a novel microfluidic approach, stem cell quantitative cytometry (SCQC), for the quantification of rare hPSCs in hPSC-derived cardiomyocyte (CM) populations. This approach enables the ultrasensitive capture, profiling, and enumeration of trace levels of hPSCs labeled with magnetic nanoparticles in a low-cost, manufacturable microfluidic chip. We deploy SCQC to assess the tumorigenic risk of hPSC-derived CM populations in vivo. In addition, we isolate rare hPSCs from the differentiated populations using SCQC and characterize their pluripotency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.